Clinical Research Directory
Browse clinical research sites, groups, and studies.
Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.
Key Details
Gender
MALE
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-05-15
Completion Date
2027-05
Last Updated
2025-07-09
Healthy Volunteers
No
Conditions
Interventions
68Ga-PSMA-CYC
Each prostate cancer patient underwent a 68Ga-PSMA-CYC (3-4 mCi) PET/CT scan, as well as a 68Ga-PSMA-617 (3-4 mCi) or 68Ga-PSMA-11 (3-4 mCi) PET/CT scan, with the time interval between the two scans not exceeding one week.
CYC
The dose will be 3-4mCi given intravenously.
Locations (1)
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China